Resistance Profiling and Molecular Characterization of Extended-Spectrum/Plasmid-Mediated AmpC β-Lactamase-Producing Escherichia coli Isolated from Healthy Broiler Chickens in South Korea

Hyun-Ju Song, Dong Chan Moon, Abraham Fikru Mechesso, Hee Young Kang, Mi Hyun Kim, Ji-Hyun Choi, Su-Jeong Kim, Soon-Seek Yoon and Suk-Kyung Lim *

Bacterial Disease Division, Animal and Plant Quarantine Agency, 177 Hyeksin 8-ro, Gimcheon-si, Gyeongsangbuk-do 39660, Korea; sjh0211@korea.kr (H.-J.S.); ansehdcks@korea.kr (D.C.M.); abrahamf@korea.kr (A.F.M.); kanghy7734@korea.kr (H.Y.K.); kimnh940301@naver.com (M.H.K.); wlguss01@korea.kr (J.-H.C.); kismujeong27@gmail.com (S.-J.K.); yoonss24@korea.kr (S.-S.Y.)

* Correspondence: imsk0049@korea.kr; Tel.: +82-5-4912-0738

Received: 1 September 2020; Accepted: 17 September 2020; Published: 18 September 2020

Abstract: We aimed to identify and characterize extended-spectrum β-lactamase (ESBL)-and/or plasmid-mediated AmpC β-lactamase (pAmpC)-producing Escherichia coli isolated from healthy broiler chickens slaughtered for human consumption in Korea. A total of 332 E. coli isolates were identified from 339 cloacal swabs in 2019. More than 90% of the isolates were resistant to multiple antimicrobials. ESBL/pAmpC-production was noted in 14% (46/332) of the isolates. Six of the CTX-M-β-lactamase-producing isolates were found to co-harbor at least one plasmid-mediated quinolone resistance gene. We observed the co-existence of blaCMY-2 and mcr-1 genes in the same isolate for the first time in Korea. Phylogenetic analysis demonstrated that the majority of blaCMY-2-carrying isolates belonged to subgroup D. Conjugation confirmed the transferability of blaCTX-M and blaCMY-2 genes, as well as non-β-lactam resistance traits from 60.9% (28/46) of the ESBL/pAmpC-producing isolates to a recipient E. coli J53. The ISECP, IS903, and orf477 elements were detected in the upstream or downstream regions. The blaCTX-M and blaCMY-2 genes mainly belonged to the IncI1, IncH12, and/or IncFII plasmids. Additionally, the majority of ESBL/pAmpC-producing isolates exhibited heterogeneous PFGE profiles. This study showed that healthy chickens act as reservoirs of ESBL/pAmpC-producing E. coli that can potentially be transmitted to humans.

Keywords: broiler; β-lactamase; blaCTX-M; blaCMY-2; E. coli; mcr-1; plasmids; quinolone

1. Introduction

Escherichia coli is a commensal bacterium of the intestinal tract of humans and animals. It constitutes a reservoir of resistance genes for a wide range of pathogenic bacteria. The level of resistance in this bacterium is a good indicator of the selection pressure exerted by antimicrobial use and for the resistance problem to be expected in related pathogenic bacteria [1]. Therefore, investigation of the antimicrobial resistance profiles of indicator bacteria, such as E. coli, is essential to detect the spread of resistant bacteria between animals and humans [2].

Healthy food animals are frequently reported as reservoirs of extended-spectrum β-lactamase (ESBL) and plasmid-mediated AmpC β-lactamase (pAmpC)-producing E. coli, and have caught considerable attention worldwide [3,4]. The ESBL/pAmpC enzymes are known to hydrolyze the β-lactam ring of β-lactam antibiotics and cause the emergence of resistance to a considerable number of β-lactam antibiotics, including extended-spectrum cephalosporins [5]. Besides,
ESBL/pAmpC-producing bacteria carry MDR genes, leaving only limited therapeutic options [6]. Human infections presumably occur following the ingestion of contaminated food of animal origin or via close contact with infected animals [7].

CTX-M-14 was the first CTX-M-type ESBL to be detected from isolates originated from food animals—i.e., *E. coli* isolated from chickens [8]. Since then, various types of CTX-M β-lactamases have been identified in *E. coli* recovered from food animals worldwide [9–13]. The distribution of CTX-M-type ESBLs varies depending upon geographical location. In the Republic of Korea (Korea), CTX-M-1, CTX-M-14, and CTX-M-15 are the most frequently detected ESBL types in isolates from food animals [14–16]. Recently, CTX-M-55 and CTX-M-65 ESBL types were noted in *E. coli* isolated from food animals and farm workers [16,17]. The observation implies that continuous surveillance of the phenotypic and molecular characteristics of ESBL/pAmpC-producing *E. coli* in food animals is vital to identify the prevalent ESBL/pAmpC phenotypes and to prevent the dissemination of β-lactam antibiotic resistance. Consequently, we undertook this study to provide new knowledge on the diversity of ESBL/pAmpC-producing *E. coli* isolated from healthy broiler chickens in Korea. Further investigations were also conducted to determine the mechanism(s) of the transfer of β-lactamases.

2. Materials and Methods

2.1. Collection of Samples and Isolation of *E. coli*

Fecal samples were collected from chickens originated from 34 broiler chicken farms located in six provinces of Korea in 2019. All broiler farms were conventional farms, with capacities of <50,000 (five farms), 50,000–100,000 (21 farms), 100,000–150,000 (six farms), and >150,000 (two farms) broilers. Cloacal swabs or fecal samples (8–12 samples per farm) were collected from six slaughterhouses using disposable sterile swabs. Samples were kept in an icebox and immediately transported to the Animal and Plant Quarantine Agency for further processing. The isolation and identification of *E. coli* were performed as described previously [18], using eosin methylene blue agar (EMB, Becton Dickinson, Sparks, MD, USA) and MacConkey agar plates (MAC, BD, Spark, MD, USA). Isolates were then confirmed by matrix-assisted laser desorption and ionization-time-of-flight mass spectrometry (MALDI-TOF, Biomerieux, Marcy L’Etoile, France). Only a single isolate per sample was considered for further assay.

2.2. Antimicrobial Susceptibility Testing

Antimicrobial resistance profiles of the isolates were determined by the broth microdilution method, according to the Clinical and Laboratory Standards Institute guideline (CLSI) [19], using commercially available Sensititre plates KRVP5F (Thermo Trek Diagnostics, Waltham, MA, USA). Sixteen antimicrobials were tested: amoxicillin/clavulanic acid, ampicillin, cefepime, cefoxitin, ceftazidime, ceftiofur, chloramphenicol, ciprofloxacin, colistin, gentamicin, meropenem, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim/sulfamethoxazole. *E. coli* ATCC 25,922 and *E. coli* ATCC 35,218 were used as quality control strains. The interpretation of the results was according to the CLSI guidelines [19], the National Antimicrobial Resistance Monitoring System [20], and the European Committee on Antimicrobial Susceptibility Testing [21] guidelines. The MIC$_{50}$ and MIC$_{90}$ were calculated as the MIC that inhibited 50% and 90% of the isolates, respectively. Multi-drug resistance (MDR) was defined as resistance to at least three antimicrobial subclasses.

In addition, a double-disc synergy test was conducted to identify ESBL-producing isolates among ceftiofur-resistant *E. coli* using cefotaxime–cefotaxime/clavulanic acid and ceftazidime–ceftazidime/clavulanic acid discs (BD, Sparks, MD, USA), according to CLSI guidelines [19].

2.3. Detection of Resistance Genes

Polymerase chain reaction (PCR) assay was performed to detect the presence of *bla*$_{CTX-M}$ genes using group-specific primers for CTX-M-1 and CTX-M-9. The complete *bla*$_{CTX-M}$ was amplified and
sequenced using previously-described primers. Additionally, a multiplex PCR assay was conducted to detect genes encoding for six AmpC families and positive isolates were amplified using specific primers. The \( \text{bla}_{\text{CTX-M}} \) and AmpC-positive strains were further screened for plasmid-mediated quinolone resistance (PMQR) genes: \( qnrA, qnrB, qnrC, qnrD, qnrS1, qnrV, qepA \), and \( \text{aac (6')} \text{ Ib-cr} \) genes. Sequence analysis was performed using ABI3730XL DNA sequence analyzer (SolGent, Daejeon, Korea) and comparison with known sequences was performed with the Basic Local Alignment Search Tool (BLAST) programs at the National Center for Biotechnology Information website (www.ncbi.nlm.nih.gov/BLAST). The primers and their PCR conditions used for the detection of resistance genes are listed in Table S1.

### 2.4. Conjugation Experiment

The broth-mating experiment was performed to determine the transferability of \( \text{bla}_{\text{CTX-M}} \) genes to sodium azide-resistant \( E. \text{coli} \) \( J53 \) [22]. Transconjugants were selected on Muller–Hinton agar, supplemented with sodium azide (150 \( \mu \text{g/mL} \)) and cefotaxime (2 \( \mu \text{g/mL} \)). The antimicrobial susceptibility profiles and \( \beta \)-lactamase gene carriage of the transconjugants were also determined, as described above.

### 2.5. Molecular Characterization of ESBL/pAmpC-Producing \( E. \text{coli} \)

A PCR-based replicon typing kit (DIATHEVA, Fano, Italy) was used to determine the replicon types of the transconjugants following the manufacturer’s protocol. The genetic environment of the \( \text{bla}_{\text{CTX-M}} \text{CMY-2} \) genes was investigated using PCR and Sanger sequencing, as described previously [23,24]. A combination of \( \text{IS26 or ISEcp1} \) forward primers, and a CTX-M reverse consensus primer (MA2) were used to investigate regions upstream of the \( \text{bla} \) genes. A \( \text{MA1} \) primer and reverse primers of \( \text{IS903 or orf477} \) were used to characterize downstream regions of the \( \text{bla} \) genes. The primers and their PCR conditions used for the detection of the \( \text{bla}_{\text{CTX-M}} \) and \( \text{bla}_{\text{CMY-2}} \) genetic environments are listed in Table S1. Additionally, pulsed-field gel electrophoresis (PFGE) analysis of ESBL/pAmpC-producing \( E. \text{coli} \) strains was also performed following XbaI digestion of chromosomal DNA (Takara Bio Inc., Shiga, Japan), as described previously [25]. Then, PFGE bands were analyzed using BioNumerics software (UPGMA) and relatedness of the isolates was calculated using the unweighted pair group method with the arithmetic average algorithm based on the Dice similarity index. Further, a multiplex PCR assay targeting \( \text{chuA}, \text{yjaA}, \) and the DNA fragment TspE4.C2 was used to determine the phylogenetic characteristics of the ESBL/pAmpC-producing strains [26].

### 3. Results

#### 3.1. Antimicrobial Resistance of Indicator \( E. \text{coli} \)

We identified 332 \( E. \text{coli} \) isolates from 339 fecal samples obtained from 34 different broiler farms. Resistance to nalidixic acid (92.5%) was the highest, followed by resistance to ampicillin (86.4%), ciprofloxacin (78.3%), and tetracycline (71.7%) (Table 1). Resistance to amoxicillin/clavulanic acid, cefepime, cefoxitin, ceftazidime, and colistin was low (0.6–3.6%). We observed ceftiofur resistance in 13.9% (46/332) of the isolates. However, resistance to meropenem was not detected. All isolates were resistant to at least one antimicrobial agent, and MDR was noted in 94.3% of the isolates (Table 2). Besides, about 34% of the isolates exhibited resistance to at least eight antimicrobials. Among 103 different resistance patterns observed in this study, resistance to ampicillin, chloramphenicol, ciprofloxacin, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim/sulfamethoxazole (12.5%) was the most frequent MDR pattern.
Table 1. Antimicrobial resistance profiles and MIC distribution of *Escherichia coli* isolated from healthy broiler chickens in Korea.

| Antimicrobials                  | ≤0.12 | 0.25 | 0.5 | 1   | 2   | 4   | 8   | 16  | 32  | 64  | 128 | 256 | ≥512 | MIC<sub>50</sub> | MIC<sub>90</sub> | MIC Range (%) |
|---------------------------------|-------|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|----------|-----------|
| Amoxicillin/clavulanic acid     | 3.6   | 10.8 | 69.9| 12.3| 3.3 | 8   | 16  | 2   | 3   | 3   | 1   | 1   | 1   | 1    | 8      | 16       | 2–32     | 3.3      |
| Ampicillin                      | 4.8   | 8.1  | 0.6 | 8.1 | 0.6 | 8   | 16  | 2   | 3   | 3   | 1   | 1   | 1   | 1    | 64     | 64       | 2–64    | 86.4     |
| Cefepime                        | 87.3  | 1.8  | 2.4 | 0.6 | 3   | 1.2 | 2   | 3   | 1   | 1   | 1   | 1   | 1   | 0.25 | 0.25  | 0.25–16 | 1.2     |
| Cefoxitin                       | 7.2   | 48.2 | 35.2| 5.7 | 3.6 | 1   | 4   | 1   | 1   | 1   | 1   | 1   | 1   | 1    | 1      | 1–32    | 3.6      |
| Ceftazidime                     | 89.5  | 1.5  | 2.4 | 3   | 3.6 | 1   | 2   | 1   | 1   | 1   | 1   | 1   | 1   | 1    | 0.5    | 0.5–8   | 13.9     |
| Cefiotur                        | 75    | 10.5 | 0.3 | 14.2| 1   | 1   | 1   | 1   | 1   | 1   | 1   | 1   | 1   | 0.5  | 8      | 0.5–8   | 13.9     |
| Chloramphenicol                 | 0.3   | 12.7 | 18.4| 1.5 | 2.1 | 65.1| 64  | 64  | 2–64| 2–64| 67.2|
| Ciprofloxacin                   | 1.8   | 11.7 | 4.8 | 1.5 | 1.8 | 2.7 | 43.7| 31.9| 8   | 16  | 0.12–16| 78.3|
| Colistin                        | 99.4  | 0.6  | 0.3 | 2.4 | 3   | 20.2| 2   | 2   | 2   | 2   | 2   | 2   | 2    | 1      | 1–64    | 25.6     |
| Gentamicin                      | 70.2  | 3.9  | 0.3 | 2.4 | 3   | 20.2| 1   | 64  | 1–64| 25.6| 0   |
| Meropenem                       | 100   | 100  | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100  | 0.25  | 0.25–0.25| 0       |
| Nalidixic Acid                  | 2.1   | 1.8  | 2.1 | 1.5 | 0.6 | 1.5 | 90.4| 128 | 128 | 2–128| 92.5|
| Streptomycin                    | 28.3  | 14.8 | 22.6| 34.3| 1   | 4   | 49.7| 49.7| 64  | 128 | 2–128| 71.7|
| Sulfisoxazole                   | 33.4  | 9.3  | 4.8 | 2.4 | 0.3 | 49.7| 1   | 4   | 0.12–4| 49.7| 0   |

The dilution ranges tested are those contained in the white area. The breakpoints of tested antimicrobial agents are indicated by vertical lines. MIC<sub>50</sub> and MIC<sub>90</sub> are the concentrations at which 50% and 90% of the isolates were inhibited, respectively.
Table 2. Frequent antimicrobial resistance patterns of *Escherichia coli* isolated from healthy broiler chickens in Korea.

| No. of Antimicrobials | Total No. of Isolates (%) | Frequent Resistance Pattern (No. of Isolates) |
|-----------------------|---------------------------|---------------------------------------------|
| 0                     | 0 (0)                     | NAL (*n* = 1)                               |
| 1                     | 1 (0.3)                   | AMP TET (*n* = 8)                           |
| 2                     | 18 (5.4)                  | AMP CIP NAL TET (*n* = 8)                   |
| 3                     | 30 (9)                    | AMP CIP NAL TET (*n* = 9)                   |
| 4                     | 26 (7.8)                  | AMP CIP NAL TET (*n* = 9)                   |
| 5                     | 53 (16)                   | AMP CHL CIP NAL TET (*n* = 16)              |
| 6                     | 34 (10.2)                 | AMP CIP GEN NAL STR TET (*n* = 4)           |
| 7                     | 58 (17.5)                 | AMP CHL CIP NAL STR FIS TET (*n* = 13)      |
| 8                     | 55 (16.6)                 | AMP CHL CIP NAL STR FIS TET SXT (*n* = 39)  |
| 9                     | 45 (13.6)                 | AMP CHL CIP GEN NAL STR FIS TET SXT (*n* = 35) |
| 10                    | 6 (1.8)                   | AMP XNL CHL CIP GEN NAL STR FIS TET SXT (*n* = 3) |
| 11                    | 2 (0.6)                   | AMC AMP FOX CAZ XNL CHL CIP NAL STR FIS TET SXT (*n* = 1) |
| 12                    | 1 (0.3)                   | AMC AMP FOX CAZ XNL CHL CIP NAL STR FIS TET SXT (*n* = 1) |
| 13                    | 3 (0.9)                   | AMC AMP FOX CAZ XNL CHL CIP COL NAL STR FIS TET SXT (*n* = 1) |
| MDR (≥3 subclass)     | 313 (94.3)                |                                             |

AMC, Amoxicillin/clavulanic acid; AMP, ampicillin; FOX, cefoxitin; CAZ, ceftazidime; XNL, ceftiofur; CHL, chloramphenicol; CIP, ciprofloxacin; COL, colistin; GEN, gentamicin; NAL, nalidixic acid; STR, streptomycin, FIS, sulfisoxazole; TET, tetracycline; SXT, Trimethoprim/Sulfamethoxazole. MDR; Multi drug resistant (resistance to 3 or more antimicrobial subclasses).
3.2. Distribution of ESBL/pAmpC-Producing E. coli

We identified 46 (13.9%) ESBL/pAmpC-producing E. coli strains from 22 (64.7%) different broiler farms (Table 3). We observed four different types of ESBLs, namely CTX-M-55 (n = 18, 39.1%), CTX-M-14 (n = 12, 26.1%), CTX-M-1 (n = 4, 8.7%), and CTX-M-65 (n = 2, 4.3%). CMY-2 is the only pAmpC detected in eight (17.4%) E. coli strains, and two (4.3%) strains were positive for both CTX-M-55 and CMY-2 β-lactamases. The prevalence of ESBL/pAmpC-producing E. coli strains among farms ranged between 9.1% and 50%. Most farms carried one (59.1%) or two (36.4%) ESBL/pAmpC-types, while we noted three different ESBL/pAmpC-types from a farm in Jeonnam province.
Table 3. Distribution of \textit{bla}_{\text{CTX-M}} \textit{and} \textit{bla}_{\text{CMY-2}}-carrying \textit{Escherichia coli} isolates in broiler chicken farms in Korea.

| Farm ID | Province   | Prevalence (%) (No. of \textit{bla}-Positive Isolates/Total No. of Isolates per Farm) | CTX-M-1 | CTX-M-14 | CTX-M-55 | CTX-M-65 | CMY-2 | CTX-M-55+CMY-2 |
|---------|------------|--------------------------------------------------------------------------------|--------|--------|--------|--------|-------|----------------|
| 2019-P-A | Chungbuk   | 12.5 (1/8)                                                                         | 1      |       |       |        |       |                 |
| 2019-P-C | Gyeongbuk  | 25 (2/8)                                                                           |        | 1     |       |        |       |                 |
| 2019-P-E | Gyeongbuk  | 27.3 (3/11)                                                                        | 1      | 2     |       |        |       |                 |
| 2019-P-G | Jeonbuk    | 10 (1/10)                                                                          |        |       | 1     |        |       |                 |
| 2019-P-I | Jeonbuk    | 50 (5/10)                                                                          | 4      |       |       |        |       |                 |
| 2019-P-K | Jeonbuk    | 20 (2/10)                                                                          |        |       |       |        |       |                 |
| 2019-P-M | Jeonnam    | 10 (1/10)                                                                          |        |       |       |        |       |                 |
| 2019-P-N | Chungbuk   | 10 (1/10)                                                                          |        |       |       |        |       | 1               |
| 2019-P-O | Gyeongbuk  | 10 (1/10)                                                                          |        |       |       |        |       |                 |
| 2019-P-P | Gyeongbuk  | 20 (2/10)                                                                          |        |       |       |        |       |                 |
| 2019-P-T | Chungnam   | 9.1 (1/11)                                                                         |        |       |       |        |       |                 |
| 2019-P-V | Jeonnam    | 10 (1/10)                                                                          |        |       |       |        |       |                 |
| 2019-P-W | Jeonbuk    | 30 (3/10)                                                                          |        |       | 2     | 1      |       |                 |
| 2019-P-Y | Jeonbuk    | 10 (1/10)                                                                          |        |       |       |        |       | 1               |
| 2019-P-Z | Chungnam   | 20 (2/10)                                                                          | 1      |       |       |        |       |                 |
| 2019-P-AA| Chungnam   | 9.1 (1/11)                                                                         |        |       |       |        |       |                 |
| 2019-P-AB| Jeonnam    | 10 (1/10)                                                                          |        |       |       |        |       | 1               |
| 2019-P-AC| Jeonbuk    | 40 (4/10)                                                                          | 1      | 3     |       | 1      |       |                 |
| 2019-P-AD| Gyeonggi   | 30 (3/10)                                                                          | 2      |       |       |        |       |                 |
| 2019-P-AE| Jeonnam    | 40 (4/10)                                                                          | 1      | 2     | 1      |       |       |                 |
| 2019-P-AF| Jeonbuk    | 20 (2/10)                                                                          |        |       |       |        |       |                 |
| 2019-P-AG| Jeonbuk    | 40 (4/10)                                                                          |        |       |       |        |       |                 |
| Total   |            | 22.4 (46/219)                                                                      | 4      | 12    | 18    | 2      | 8     | 2               |

The numbers in columns 4–9 represent the number of isolates that carried \textit{bla}_{\text{CTX-M}} \textit{and/or} \textit{bla}_{\text{CMY-2}} genes.
3.3. Molecular Characteristics of ESBL/pAmpC-Producing E. coli

The ESBL/pAmpC-producing isolates exhibited resistance to several antimicrobial classes, such as aminoglycoside, tetracycline, quinolones, and folate pathway inhibitors (Table 4). Six of the CTX-M β-lactamase-producing isolates were found to co-harbor at least one PMQR gene, with qnrS1, qnrS2, and aac (6′)-Ib-cr being detected alone or in combination. Notably, the blaCTX-M-65, qnrS2, and aac (6′)-Ib-cr genes were found to be carried together in one isolate. Additionally, one isolate from farm E co-carried blaCMY-2 and mcr-1 genes.

The blaCTX-M and blaCMY-2 genes were transferred to recipient E. coli J53 from 55.3% (21/38) of blaCTX-M-positive (three blaCTX-M-1, five blaCTX-M-14, and 13 blaCTX-M-55) and 70% (7/10) of blaCMY-2-positive E. coli strains (Table 4). In addition, we observed the co-transfer of non-β-lactam antibiotic resistance, such as resistance to chloramphenicol, sulfisoxazole, tetracycline, and aminoglycosides along with blaCTX-M and blaCMY-2 genes.

We identified various plasmid replicon types including IncI1α, IncFIB, IncFII, and IncHI2. IncFII (60.7%, 17/28) and IncI1α (35.7%, 10/28) were the most frequent plasmid replicon types (Tables 4 and 5). Multiple replicon types were observed in 39.3% (11/28) of the transconjugants. Plasmids harboring blaCTX-M-1 and blaCMY-2 genes mainly belonged to IncI1α replicon type. Whereas, plasmids harboring blaCTX-M-14 and blaCTX-M-55 genes were predominantly associated with IncHI2 and IncFII replicon types, respectively.

The transconjugants carrying the blaCTX-M-55 gene presented distinct types of genetic environments, namely blaCTX-M-55orf477 (n = 9) and ISEcp1-blaCTX-M-55orf477 (n = 4) elements (Table 5). ISEcp1-blaCTX-M-1orf477 and blaCTX-M-14-IS903 elements were identified in three and five transconjugants, respectively. The blaCMY-2 and blaCTX-M-55+CMY-2 gene expression was driven by the ISEcp1 insertion sequence, but IS903 and orf477 elements were not detected downstream of blaCMY-2 and blaCTX-M-55+CMY-2 genes.

PFGE analysis of 46 E. coli strains carrying blaCTX-M and blaCMY-2 genes from 21 different farms demonstrated 34 arbitrary pulsotypes (Figure S1). In general, most of the isolates were heterogeneous. We observed identical PFGE profiles in blaCTX-M-14, blaCTX-M-55, and blaCTX-M-65-carrying strains from farms AC, AE, AG, and I. Similarly, the two blaCTX-M-14-carrying isolates from farms AC and AE exhibited identical PFGE profiles. However, DNA from five strains was constantly auto-digested. Consequently, a cluster formed by these strains was excluded from the analysis.

Phylogenetic analysis of ESBL/pAmpC-producing strains showed that subgroup B1 was predominant (20/46, 43.5%), followed by A (20/46, 39.1%) and D (8/46, 17.4%). Notably, most blaCMY-2 carrying isolates (6/8, 75%) belonged to subgroup D.
Table 4. Characteristics of ESBL/pAmpC-producing *Escherichia coli* isolated from healthy broiler chickens in Korea.

| Isolates | Farm ID | Provinces | MICs (µg/mL) | bla Gene | PMQR Gene | Non-β Lactam Antibiotic Resistance | Transferability | Plasmid Type | Phylogenetic Group | Pulsotype |
|----------|---------|-----------|--------------|----------|-----------|-----------------------------------|----------------|-------------|-------------------|-----------|
| A-CF-6   | A       | Chungbuk  | >8 4 4       | CTX-M-55 | -         | CIP NAL                           | +              | FII         | A                | P22       |
| C-CF-6   | C       | Gyeongbuk | >8 8 2       | CTX-M-1  | qnrS1     | CHL GEN STR FIS TET SXT           | +              | IIα, FIB    | A                | P9        |
| C-CF-8   | C       | Gyeongbuk | >8 8 4       | CTX-M-55 | qnrS1     | CHL FIS                           | +              | IIα, FII    | D                | P6        |
| E-CF-2   | E       | Gyeongbuk | >8 32 16     | CMY-2    |           | AMC STR FIS TET SXT               | -              | -           | D                | P31       |
| E-CF-M-5 | E       | Gyeongbuk | >8 >32 16    | CMY-2    | mcr-1     | CHL CIP COL, NAL STR FIS TET SXT  | +              | IIα, FII    | D                | P32       |
| E-CF-8   | E       | Gyeongbuk | 8 8 ≤1       | CTX-M-14 | -         | CHL CIP NAL FIS                   | +              | H12, Iγ, FII | A                | P26       |
| G-CF-M-6 | G       | Jeonbuk   | >8 >32 >16   | CMY-2    |           | CHL CIP NAL STR FIS TET SXT       | +              | IIα         | A                | P34       |
| I-CF-1   | I       | Jeonbuk   | >8 2 4       | CTX-M-55 | qnrS1     | CIP GEN NAL                       | -              | -           | A                | P2        |
| I-CF-M-2 | I       | Jeonbuk   | >8 4 ≤1      | CTX-M-14 | -         | CIP GEN NAL                       | -              | -           | A                | P2        |
| I-CF-5   | I       | Jeonbuk   | >8 4 ≤1      | CTX-M-14 | -         | CIP GEN NAL                       | -              | -           | A                | P1        |
| I-CF-M-7 | I       | Jeonbuk   | >8 4 ≤1      | CTX-M-14 | -         | CIP GEN NAL                       | -              | -           | A                | P1        |
| I-CF-M-8 | I       | Jeonbuk   | >8 2 ≤1      | CTX-M-14 | -         | CIP GEN NAL                       | -              | -           | A                | P1        |
| K-CF-M-1 | K       | Jeonbuk   | >8 >32 >16   | CMY-2    |           | CHL CIP NAL TET                   | +              | IIα, FIB    | D                | ND        |
| K-CF-7   | K       | Jeonbuk   | >8 32 16     | CMY-2    |           | CIP NAL                           | -              | -           | D                | ND        |
| M-CF-M-3 | M       | Jeonnam   | >8 8 8       | CTX-M-55 |          | CIP NAL                           | -              | -           | B1               | ND        |
| N-CF-5   | N       | Chungbuk  | >8 >32 16    | CTX-M-55 |          | CHL CIP NAL STR FIS               | +              | K, X4       | D                | P27       |
| O-CF-4   | O       | Gyeongbuk | >8 4 2       | CTX-M-1  | -         | NAL FIS TET                       | +              | IIα         | A                | P10       |
| P-CF-M-2 | P       | Gyeongbuk | >8 8 4       | CTX-M-55 |          | CIP NAL                           | +              | FII         | A                | P20       |
| P-CF-9   | P       | Gyeongbuk | >8 2 ≤1      | CTX-M-14 | -         | CIP GEN NAL TET                   | -              | -           | A                | P4        |
| T-CF-M-3 | T       | Chungbuk  | >8 4 2       | CTX-M-1  | -         | CHL CIP NAL FIS TET               | +              | IIα         | B1               | P21       |
| V-CF-2   | V       | Jeonnam   | >8 4 8       | CTX-M-55 |          | CHL CIP NAL STR FIS TET           | -              | B1          | P11              |           |
| W-CF-M-5 | W       | Jeonbuk   | >8 4 8       | CTX-M-55 |          | CIP GEN NAL TET                   | +              | IIα, FIB    | D                | P24       |
| W-CF-6   | W       | Jeonbuk   | >8 8 8       | CTX-M-55 |          | CHL CIP NAL TET                   | +              | FII         | B1               | P14       |
| W-CF-M-10| W       | Jeonbuk   | >8 32 >16    | CTX-M-55, CMY-2 |          | CHL CIP NAL STR FIS TET SXT   | -              | B1          | P25              |           |
| Y-CF-4   | Y       | Jeonbuk   | >8 4 8       | CTX-M-55 | qnrS1     | TET                               | +              | FII         | B1               | P5        |
| Z-CF-M-1 | Z       | Chungnam  | 8 >32 8      | CMY-2    |           | CHL CIP NAL STR FIS TET           | +              | K           | B1               | P29       |
| Z-CF-7   | Z       | Chungnam  | >8 4 2       | CTX-M-1  |          | CIP NAL                            | -              | -           | B1               | P28       |
| AA-CF-M-2| AA      | Chungnam  | >8 4 4       | CTX-M-55 |          | CIP NAL                            | +              | FIB, FII    | B1               | P23       |
| AB-CF-M-1| AB      | Jeonbuk   | >8 >32 16    | CMY-2    |           | CHL CIP NAL STR FIS TET           | +              | IIα         | D                | P33       |
| AC-CF-2  | AC      | Jeonbuk   | >8 32 >16    | CTX-M-55 |          | CHL CIP NAL FIS                   | -              | -           | B1               | P13       |
| Isolates  | Farm ID | Provinces | MICs (µg/mL) | bla Gene | PMQR Gene | Non-β Lactam Antibiotic Resistance | Transfer-Ability | Plasmid Type | Phylogenetic Group | Pulsotype |
|-----------|---------|-----------|--------------|----------|-----------|-----------------------------------|----------------|--------------|----------------|-----------|
| AC-CF-M-3 | AC      | Jeonbuk   | >8 4 4       | CTX-M-55 | -         | CHL CIP NAL STR FIS SXT           | +              | FII          | A              | P15       |
| AC-CF-M-5 | AC      | Jeonbuk   | >8 8 16      | CTX-M-55 | -         | CHL CIP NAL FIS TET              | -              | B1           | P13           |
| AC-CF-10  | AC      | Jeonbuk   | >8 2 ≤1      | CTX-M-14 | -         | CIP GEN NAL                       | -              | A            | P3            |
| AD-CF-M-2 | AD      | Gyeonggi  | 8 8 ≤1      | CTX-M-14 | -         | CHL CIP GEN NAL FIS TET SXT       | +              | HI2, I1α     | B1            | P18       |
| AD-CF-8   | AD      | Gyeonggi  | 8 16 ≤1     | CTX-M-14 | -         | CHL CIP GEN NAL STR FIS TET       | +              | HI2          | B1            | P16       |
| AD-CF-M-10| AD      | Gyeonggi  | >8 4 8      | CTX-M-55 | -         | CHL CIP NAL FIS TET SXT           | -              | A            | P8            |
| AE-CF-M-1 | AE      | Jeonnam   | >8 >32 16   | CMY-2    | qnrS2, aac(6’)-Ib-cr | CHL CIP GEN NAL STR FIS TET SXT | +              | I1α          | B1            | P30       |
| AE-CF-4   | AE      | Jeonnam   | >8 2 ≤1     | CTX-M-14 | -         | CHL CIP GEN NAL STR FIS TET SXT   | -              | A            | P3            |
| AE-CF-M-9 | AE      | Jeonnam   | >8 8 ≤1     | CTX-M-65 | aac(6’)-Ib-cr | CHL CIP GEN NAL STR FIS TET SXT   | -              | B1           | P12           |
| AE-CF-M-10| AE      | Jeonnam   | >8 8 2      | CTX-M-65 | aac(6’)-Ib-cr | CHL CIP GEN NAL STR FIS TET SXT   | -              | B1           | P12           |
| AF-CF-M-1 | AF      | Jeonbuk   | 8 4 ≤1      | CTX-M-14 | -         | CHL CIP GEN NAL FIS TET SXT       | +              | HI2          | B1            | ND        |
| AF-CF-M-4 | AF      | Jeonbuk   | >8 4 ≤1     | CTX-M-14 | -         | CHL CIP GEN NAL FIS TET SXT       | +              | HI2          | B1            | ND        |
| AG-CF-M-4 | AG      | Jeonbuk   | >8 8 8      | CTX-M-55 | -         | CHL CIP GEN NAL FIS TET SXT       | +              | FII          | A             | P19       |
| AG-CF-6   | AG      | Jeonbuk   | >8 4 8      | CTX-M-55 | -         | CHL CIP NAL FIS TET SXT           | +              | FII          | A             | P19       |
| AG-CF-M-9 | AG      | Jeonbuk   | >8 8 8      | CTX-M-55 | -         | CHL CIP NAL FIS TET SXT           | +              | FII          | A             | P19       |
| AG-CF-M-10| AG      | Jeonbuk   | >8 4 4      | CTX-M-55 | -         | CHL STR FIS TET                    | +              | I1α, FII     | B1            | P17       |

AMC, Amoxicillin/clavulanic acid; CAZ, Ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; COL, colistin; FOX, cefoxitin; GEN, gentamicin; NAL, nalidixic acid; STR, streptomycin; FIS, sulfisoxazole; TET, tetracycline; SXT, Trimethoprim/sulfamethoxazole; XNL, ceftiofur. PMQR, plasmid-mediated quinolone resistance. *XbaI* macrorestriction analysis yielded no DNA banding patterns in five *E. coli* isolates due to constant autodigestion of the genomic DNA, and thus, a cluster formed by this strain is excluded (ND, not determined). The underlined resistance markers were transferred to the recipient *E. coli* J53 strain by conjugation.
Table 5. Plasmid replicon types and genetic environments of ESBL/pAmpC gene-carrying E. coli transconjugants.

| Type of bla Gene | No. of Isolates | Self-Transfer | No. of Replicon Type | Genetic Environment |
|------------------|-----------------|---------------|----------------------|---------------------|
|                  |                 |               | I1α | I1α + FII | I1α + FII + FIB | FII | FII + FIB | HI2 | HI2 + I1α | HI2 + FII + Iy | K | B/O + K + X4 | Upstream | Downstream |
| CTX-M-1          | 4               | 3             | 2   | -        | 1               | -   | -         | -   | -         | -               | 3 | -          | -        | -         |
| CTX-M-14         | 12              | 5             | -   | -        | -               | -   | 3         | 1   | 1         |       | -       | -        | -         |
| CTX-M-55 a       | 11              | 9             | -   | -        | 1               | 8   | -         | -   | -         |       | -       | -        | 9         |
| CTX-M-55 b       | 7               | 4             | -   | -        | 1               | 1   | 1         | -   | -         |       | 4       | -        | 4         |
| CTX-M-65         | 2               | 0             | -   | -        | -               | -   | -         | -   | -         | 1   | -       | -        | -         |
| CMY-2            | 8               | 6             | 3   | 1        | 1               | -   | -         | -   | -         | 1   | -       | 6        | -         |
| CTX-M-55+CMY-2   | 2               | 1             | -   | -        | -               | -   | -         | -   | 1         | 1   | -       | -        | -         |
| Total            | 46              | 28            | 5   | 3        | 3               | 9   | 1         | 3   | 1         | 1    | 1       | 14       | 0         |

a blaCTX-M-55-orf477, b ISEcp1-blaCTX-M-55-orf477.
4. Discussion

Our observations revealed that most of *E. coli* isolated from healthy broilers were resistant to multiple antimicrobials and possessed diverse ESBL-encoding genes that could be readily spread to humans. Although CTX-M-15 is considered the predominant ESBL type in the Korean poultry industry [27], we observed CTX-M-14 and CTX-M-55 type ESBLs in most of the isolates.

Consistent with previous findings in Korea [28,29] and other countries [30–33], *E. coli* isolates exhibited high rates of resistance to ampicillin, nalidixic acid, tetracycline, and sulfisoxazole. However, it was lower than those described in recent reports in Asia and Africa [34–36]. Additionally, the proportion of MDR isolates in this study corresponded with previous reports [28,33]. The isolates exhibited more than 100 different resistance patterns and most of these patterns were associated with quinolones, penicillins, and tetracyclines. High antimicrobial resistance rates and diverse resistance patterns observed in this study coincide with the marked increase in the use of antimicrobials, including penicillins, fluoroquinolones, phenicols, and tetracyclines in the Korean poultry industry [37]. The variations in antimicrobial resistance among countries might be because of differences in geographical region, locally approved antimicrobials, and farm management systems.

Fluoroquinolones are considered critically important antimicrobials for both humans and animals [38]. About 80% of the isolates were resistant to ciprofloxacin, a finding which is consistent with previous reports in Poland [32], Korea [39], and Vietnam [40]. However, it was higher than those reported in several Asian countries [31,35,41–43]. Although ciprofloxacin is not approved for animal uses, the continuous utilization of enrofloxacin in food animals, especially chickens in Korea, could be contributing to the increase in ciprofloxacin resistance [37].

Third-generation cephalosporin-resistant isolates are often resistant to multiple antimicrobials and are considered a potential threat to animal and human health [44]. The ceftiofur resistant rate in this study was slightly higher than previous reports in Korea (12%) [45] and the US (7%) [46]. Nevertheless, it was lower than Lee et al. (22%) [47] and Zhang et al. (47%) [33] in Korea and China, respectively. Various authors reported the relationship between ceftiofur use and resistance to third-generation cephalosporins in poultry production [48–50]. Therefore, although information on the use of this antimicrobial in farms was not available, the frequent application of ceftiofur in food animals could lead to the emergence of ceftiofur-resistant *E. coli* isolates.

A variety of ESBL/pAmpC genes have been identified in bacteria isolated from food animals worldwide. Most noteworthy of these are the *bla*<sub>CTX-M-14</sub>, *bla*<sub>CTX-M-15</sub>, *bla*<sub>CTX-M-27</sub>, and *bla*<sub>CTX-M-55</sub> variants, which have been associated with the global spread of β-lactam antibiotic resistance in humans and food animals [51,52]. In Korea, β-lactam antibiotics resistance in chicken [14,16,28] and human [53–55] isolates is commonly associated with *bla*<sub>CTX-M-1</sub>, *bla*<sub>CTX-M-14</sub>, and *bla*<sub>CTX-M-15</sub>. However, *bla*<sub>CTX-M-55</sub> was the most frequent ESBL gene observed in this study. Our finding concurred with a recent report in *E. coli* strains from retail chicken meat in Korea [17]. CTX-M-55 is a CTX-M-15 variant that possesses enhanced β-lactamase-hydrolyzing activity and structural stability [56]. Since its first detection in ESBL-producing *E. coli* in 2004 and 2005 in Thailand, it has been widely reported in *E. coli* isolated from food animals and humans in many countries [17,48,57–60]. The observation suggests that CTX-M-55 may be supplanting CTX-M-15.

*E. coli* harboring *bla*<sub>CTX-M-14</sub> has been frequently detected in food animals in Korea [14,16,22] and other countries [57,60]. In this study, *bla*<sub>CTX-M-14</sub> (26.1%) was the second most frequent ESBL gene. Similarly, Park et al. [17] and Seo et al. [28] detected *bla*<sub>CTX-M-14</sub> in 22% and 14% of ESBL-producing broiler chicken *E. coli* isolates in Korea, respectively. Additional studies have also observed *bla*<sub>CTX-M-14</sub>-carrying *E. coli* isolates in food and companion animals, as well as in humans in several Asian countries [52–54, 61,62], indicating its widespread distribution and the potential threat to public health.

In this study, only a few isolates were positive for *bla*<sub>CTX-M-1</sub> and *bla*<sub>CTX-M-65</sub>. *bla*<sub>CTX-M-65</sub> was frequently detected in ESBL-producing *E. coli* isolated from chicken in Korea [16,17] and China [52]. Although *bla*<sub>CTX-M-1</sub> was detected in ESBL-producing strains recovered from chickens and farm environments in Korea [14,22,28], it is among the most frequent ESBL-encoding gene reported in
The widespread use of quinolones and third-generation cephalosporins in food animals has led to the distribution of Enterobacteriaceae genes, compared to the ESBLs [65]. We detected the blaCMY-2 gene in 21.3% of the ceftiofur-resistant isolates. Agreeing with this study, blaCMY-2 was the most common pAmpC β-lactamase-encoding gene in E. coli recovered from broiler chickens and humans worldwide [15,66–71]. The distribution of blaCMY-2 in several countries appears to be related to the efficient horizontal transmission of its encoding plasmids [72].

PMQR genes were commonly associated with low-level fluoroquinolone resistance and promoted the selection of high-level resistant strains [73]. In this study, the PMQR genes were identified in association with blaCTX-M-1, blaCTX-M-55, and blaCTX-M-65 genes. Most of the PMQR genes were associated with blaCTX-M-55. The blaCTX-M-55 genes commonly co-localize with other resistance genes, such as PMQR genes and genes encoding 16S rRNA methyltransferases [74,75]. The co-existence of PMQR and ESBL genes in Enterobacteriaceae have been reported in many countries, including Korea [73,76–78]. The widespread use of quinolones and third-generation cephalosporins in food animals has led to the emergence of PMQR and ESBL-producing E. coli. The co-occurrence of these genes in chicken isolates constitutes a public health concern.

The co-existence of ESBL and mcr-1 genes in Enterobacteriaceae poses a serious public health threat. Despite several reports on the co-existence of mcr-1 and ESBL genes in E. coli strains isolated from humans, food animals, and fresh vegetables in various countries [52,79–83], only a few reports are available on the co-existence of mcr-1 and blaCMY-2 in E. coli [84–86]. Notably, this is the first report on the co-existence of mcr-1 and blaCMY-2 in E. coli in Korea. Colistin is the last-resort antibiotic against multidrug-resistant E. coli, hence the co-existence of mcr-1 and blaCMY-2 poses a serious challenge to the application of antimicrobials in humans and animals.

Various plasmid replicon types, either alone or in combination, were identified in E. coli transconjugants. Several studies have reported the association between blaCTX-M-14 gene and different plasmid types, including IncF family plasmids, IncK, and IncI1, respectively [12,87,88]. However, this study identified the blaCTX-M-14 gene predominantly on the IncH12 plasmid. The blaCTX-M-55 gene was efficiently transferred to recipient E. coli from 72% of blaCTX-M-55-carrying strains. This is presumably due to its frequent association with the IncF family of plasmids [27]. The IncF plasmid family is implicated in the dissemination of ESBLs because it is stably maintained in commensal E. coli [51]. In addition, the blaCTX-M-1 and blaCMY-2 genes predominantly belonged to IncI1α plasmid, a finding which concurred with Bevan et al. [51] and Carattoli, [7]. Further, the observation of diverse plasmid backbones in this study may reflect the co-occurrence of antimicrobial-resistant genes [27] and the dissemination of co-resistant bacteria [89].

ESBL-genes are often associated with insertion sequences (ISs), which are the smallest transposable elements capable of independent transposition in an organism [90]. The co-existence of ISEcp1 and ESBL/pAmpC genes in E. coli isolates is well documented [90–92]. Agreeing with this study, ISEcp1 is frequently found in the upstream regions of ESBL/pAmpC genes and plays an important role in the efficient capture, expression, and mobilization of blaCTX-M and blaCMY-2 genes [24,90]. Agreeing with previous reports [10,23,93], the orf477 element was found downstream of blaCTX-M-1 and blaCTX-M-55 genes, while IS903 was located downstream of blaCTX-M-55.

PFGE analysis demonstrated that the majority of the blaCTX-M-carrying isolates were highly diverse, except for specific clonal strains from the same or different farms, whereas all blaCMY-2-positive isolates showed different PFGE patterns. Therefore, clonal expansion and horizontal transmission within and between farms might contribute to the spread of ESBL/pAmpC-producing E. coli isolates. The proportion of subgroup D, which is considered pathogenic or an extraintestinal virulence-associated strain in our study (17.4%) was lower than Song et al. [27] (31%). The majority (82.6%) of ESBL/pAmpC-producing isolates in the current study mainly belonged to the commensal subgroups A or B1, which coincides

Europe [61,63,64]. blaCTX-M is known to spread between animals and humans through the food chain and isolates of humans and foods of animal origin commonly shared dominant CTX-M genotypes. Thus, broiler chickens may serve as an important reservoir and source of human infection [51].

pAmpC β-lactamase enzymes such as CMY-2 are less frequent in ceftiofur-resistant Enterobacteriaceae compared to the ESBLs [65]. We detected the blaCMY-2 gene in 21.3% of the ceftiofur-resistant isolates. Agreeing with this study, blaCMY-2 was the most common pAmpC β-lactamase-encoding gene in E. coli recovered from broiler chickens and humans worldwide [15,66–71]. The distribution of blaCMY-2 in several countries appears to be related to the efficient horizontal transmission of its encoding plasmids [72].
with previous reports in Korea [27] and China [60]. Most of the pathogenic strains predominantly carried bla<sub>CMY-2</sub>, suggesting the emergence of pathogenic strains of <i>E. coli</i> carrying quinolone resistance genes in the Korean poultry industry.

In conclusion, our study showed that healthy broiler chickens were a major reservoir of <i>E. coli</i> that are resistant to multiple antimicrobials, including those ranked as medically important. This study identified ESBL/pAmpC-producing <i>E. coli</i> strains carrying predominantly bla<sub>CTX-M-14</sub>, bla<sub>CTX-M-55</sub>, and bla<sub>CMY-2</sub> genes. Notably, the majority of bla<sub>CMY-2</sub>-carrying strains were pathogenic. This is the first report on the co-existence of <i>mcr-1</i> and bla<sub>CMY-2</sub> in pathogenic <i>E. coli</i> in Korea. Both horizontal and clonal spread could be implicated in the dissemination of ESBL/pAmpC-producing <i>E. coli</i>. However, the multilocus sequence types of the isolates remained unclear. Altogether, the results suggest that healthy chickens are a matter of concern in terms of transmission of ESBL/pAmpC-producing <i>E. coli</i> to humans through the food chain. Therefore, the prudent use of antimicrobials in food animals is needed to prevent the introduction of ESBL/pAmpC-producing isolates into the food chain. Additionally, long-term surveillance is needed to trace the evolution and dissemination of ESBL/pAmpC-producing <i>E. coli</i> in food animals and its possible association with human isolates.

**Supplementary Materials:** The following are available online at http:\!/\!/www.mdpi.com/2076-2607/8/9/1434/s1,
Table S1: Lists of primer sequences and PCR conditions. Figure S1: Xbal-digested pulsed-field gel electrophoresis patterns of bla<sub>CTX-M</sub> and bla<sub>CMY-2</sub> carrying <i>E. coli</i> strains isolated from healthy broiler chickens in Korea. Xbal macrorestriction analysis yielded no DNA banding patterns in five <i>E. coli</i> strain due to constant autodigestion of the genomic DNA during agarose plug preparation, and thus clusters formed by these strains were excluded (ND, not determined).

**Author Contributions:** Conceptualization, S.-K.L. and D.C.M.; Methodology, H.Y.K., H.-J.S., and S.-K.L.; Software, H.Y.K., J.-H.C., and S.-J.K.; Validation, A.F.M. and M.H.K.; Formal analysis, H.-J.S., and M.H.K.; Investigation, A.F.M., H.Y.K., H.-J.S., M.H.K., J.-H.C., and S.-J.K.; Data Curation, D.C.M., H.-J.S., and M.H.K.; Writing—Original Draft Preparation, A.F.M. and H.-J.S.; Writing—Review and Editing, S.-S.Y., S.-K.L., and D.C.M.; Supervision, S.-S.Y., S.-K.L., and D.C.M.; Project Administration, D.C.M. and H.Y.K.; Funding Acquisition; S.-K.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded from the Animal and Plant Quarantine Agency, Ministry of Agriculture, Food, and Rural affairs, Korea, grant number N-1543081-2017-24-1 and the Korean Center for Disease Control and Prevention, grant number 2017N-ER5407-00.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Lester, S.C.; Pla, M.D.P.; Wang, F.; Schael, I.P.; Jiang, H.; O’Brien, T.F. The carriage of <i>Escherichia coli</i> resistant to antimicrobial agents by healthy children in Boston, in caracas, Venezuela, and in Qin Pu, China. <i>N. Engl. J. Med.</i> 1990, 323, 285–289. [CrossRef] [PubMed]
2. Van Den Bogaard, A.E.; Stobberingh, E.E. Epidemiology of resistance to antibiotics: Links between animals and humans. <i>Int. J. Antimicrob. Agents</i> 2000, 14, 327–335. [CrossRef]
3. Alonso, C.A.; Zarazaga, M.; Ben Sallem, R.; Jouini, A.; Ben Slama, K.; Torres, C. Antibiotic resistance in <i>Escherichia coli</i> in husbandry animals: The African perspective. <i>Lett. Appl. Microbiol.</i> 2017, 64, 318–334. [CrossRef]
4. Lazarus, B.; Paterson, D.L.; Mollinger, J.L.; Rogers, B.A. Do human extraintestinal <i>Escherichia coli</i> infections resistant to expanded-spectrum cephalosporins originate from food-producing animals? A systematic review. <i>Clin. Infect. Dis.</i> 2015, 60, 439–452. [CrossRef]
5. Pitout, J.D.; Laupland, K.B. Extended-spectrum β-lactamase-producing <i>Enterobacteriaceae</i>: An emerging public-health concern. <i>Lancet Infect. Dis.</i> 2008, 8, 159–166. [CrossRef]
6. Chong, Y.; Ito, Y.; Kamimura, T. Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>. <i>Infect. Genet. Evol.</i> 2011, 11, 1499–1504. [CrossRef]
7. Carattoli, A. Resistance plasmid families in <i>Enterobacteriaceae</i>. <i>Antimicrob. Agents Chemother.</i> 2009, 53, 2227–2238. [CrossRef]
8. Briñas, L.; Moreno, M.A.; Zarazaga, M.; Porreró, C.; Sáenz, Y.; García, M.; Domínguez, L.; Torres, C. Detection of CMY-2, CTX-M-14, and SHV-12 β-lactamases in Escherichia coli fecal-sample isolates from healthy chickens. *Antimicrob. Agents Chemother.* 2003, 47, 2056–2058. [CrossRef]

9. Duan, R.S.; Sit, T.H.C.; Wong, S.S.Y.; Wong, R.C.W.; Chow, K.H.; Mak, G.C.; Ng, L.T.; Yam, W.C.; Yuen, K.Y.; Ho, P.L. *Escherichia coli* producing CTX-M β-lactamases in food animals in Hong Kong. *Microb. Drug Resist.* 2006, 12, 145–148. [CrossRef]

10. Kim, J.; Bae, I.K.; Jeong, S.H.; Chang, C.L.; Lee, C.H.; Lee, K. Characterization of IncF plasmids carrying the bla_{CTX-M-14} gene in clinical isolates of *Escherichia coli* from Korea. *J. Antimicrob. Chemother.* 2011, 66, 1263–1268. [CrossRef]

11. Madec, J.Y.; Lazizzera, C.; Châtre, P.; Meunier, D.; Martin, S.; Lepage, G.; Ménard, M.F.; Lebreton, P.; Rambaud, T. Prevalence of fecal carriage of acquired expanded-spectrum cephalosporin resistance in *Enterobacteriaceae* strains from cattle in France. *J. Clin. Microbiol.* 2008, 46, 1566–1567. [CrossRef] [PubMed]

12. Tamang, M.D.; Nam, H.M.; Kim, S.R.; Chae, M.H.; Jang, G.C.; Jung, S.C.; Lim, S.K. Prevalence and molecular characterization of CTX-M β-lactamase-producing *Escherichia coli* isolated from healthy swine and cattle. *Foodborne Pathog. Dis.* 2013, 10, 13–20. [CrossRef] [PubMed]

13. Wittum, T.E.; Mollenkopf, D.F.; Daniels, J.B.; Parkinson, A.E.; Mathews, J.L.; Fry, P.R.; Abley, M.J.; Gebreyes, W.A. CTX-M-type extended-spectrum β-lactamases present in *Escherichia coli* from the feces of cattle in Ohio, United States. *Foodborne Pathog. Dis.* 2010, 7, 1575–1579. [CrossRef] [PubMed]

14. Jo, S.J.; Woo, G.J. Molecular characterization of plasmids encoding CTX-M β-Lactamases and their associated addiction systems circulating among *Escherichia coli* from retail chickens, chicken farms, and slaughterhouses in Korea. *J. Microbiol. Biotechnol.* 2015, 26, 270–276. [CrossRef]

15. Shim, J.B.; Seo, K.W.; Kim, Y.B.; Jeon, H.Y.; Lim, S.K.; Lee, Y.J. Molecular characteristics of extended-spectrum and plasmid-mediated AmpC β-lactamase-producing *Escherichia coli* isolated from commercial layer in Korea. *Poult. Sci.* 2019, 98, 949–956. [CrossRef]

16. Shin, S.W.; Jung, M.; Won, H.G.; Belaynehe, K.M.; Yoon, I.J.; Yoo, H.J.; Yoo, H.S. Characteristics of transmissible CTX-M-and CMY-Type β-lactamase-producing *Escherichia coli* isolates collected from pig and chicken farms in South Korea. *J. Microbiol. Biotechnol.* 2017, 27, 1716–1723. [CrossRef]

17. Park, H.; Kim, J.; Ryu, S.; Jeon, B. Predominance of bla_{CTX-M-65} and bla_{CTX-M-55} in extended-spectrum β-lactamase-producing *Escherichia coli* from raw retail chicken in South Korea. *J. Glob. Antimicrob. Resist.* 2019, 17, 216–220. [CrossRef]

18. Tamang, M.D.; Nam, H.M.; Gurung, M.; Jang, G.C.; Kim, S.R.; Jung, S.C.; Park, Y.H.; Lim, S.K. Molecular characterization of CTX-M-β-lactamase and associated addiction systems in *Escherichia coli* circulating among cattle, farm workers, and the farm environment. *Appl. Environ. Microbiol.* 2013, 79, 3898–3905. [CrossRef]

19. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement; Document M100; CLSI*: Wayne, PA, USA, 2018.

20. National Antimicrobial Resistance Monitoring System. *NARMS Integrated Report: The National Antimicrobial Resistance Monitoring System: Enteric Bacteria; U.S. Food and Drug Administration*: Rockville, MD, USA, 2014.

21. European Committee on Antimicrobial Susceptibility Testing. *Breakpoint Tables for Interpretation of MICs and Zone Diameters. EUCAST, 2018, Version 8.1*. Available online: http://www.eucast.org (accessed on 15 June 2020).

22. Tamang, M.D.; Gurung, M.; Kang, M.S.; Nam, H.M.; Moon, D.C.; Jang, G.C.; Jung, S.C.; Park, Y.H.; Lim, S.K. Characterization of plasmids encoding CTX-M β-lactamase and their addiction systems in *Escherichia coli* isolates from animals. *Vet. Microbiol.* 2014, 174, 456–462. [CrossRef]

23. Eckert, C.; Gautier, V.; Arlet, G. DNA sequence analysis of the genetic environment of various bla_{CTX-M} genes. *J. Antimicrob. Chemother.* 2006, 57, 14–23. [CrossRef]

24. Saladin, M.; Cao, V.T.B.; Lambert, T.; Donay, J.L.; Herrmann, J.L.; Ould-Hocine, Z.; Verdet, C.; Delisle, F.; Philippin, A.; Arlet, G. Diversity of CTX-M β-lactamases and their promoter regions from *Enterobacteriaceae* isolated in three Parisian hospitals. *FEMS Microbiol. Lett.* 2002, 209, 161–168. [CrossRef]

25. Gautom, R.K. Rapid pulsed-field gel electrophoresis protocol for typing of *Escherichia coli* O157:H7 and other Gram-negative organisms in 1 day. *J. Clin. Microbiol.* 1997, 35, 2977–2980. [CrossRef] [PubMed]

26. Clermont, O.; Bonacorsi, S.; Bingen, E. Rapid and simple determination of the *Escherichia coli* phylogenetic group. *Appl. Environ. Microbiol.* 2000, 66, 4555–4558. [CrossRef]
27. Song, J.; Oh, S.S.; Kim, J.; Park, S.; Shin, J. Clinically relevant extended-spectrum β-lactamase–producing *Escherichia coli* isolates from food animals in South Korea. *Front. Microbiol.* 2020, 11, 604. [CrossRef] [PubMed]

28. Seo, K.W.; Kim, Y.B.; Jeon, H.Y.; Lim, S.K.; Lee, Y.J. Comparative genetic characterization of third-generation cephalosporin-resistant *Escherichia coli* from chicken meat produced by integrated broiler operations in South Korea. *Poult. Sci.* 2018, 97, 2871–2879. [CrossRef]

29. Seo, K.W.; Lee, Y.J. Prevalence and characterization of β-lactamases genes and class 1 integrons in multidrug-resistant *Escherichia coli* isolates from chicken meat in Korea. *Microb. Drug Resist.* 2018, 24, 1599–1606. [CrossRef]

30. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2012. *EFSA J.* 2014, 12, 3547. [CrossRef]

31. Lei, T.; Tian, W.; He, L.; Huang, X.H.; Sun, Y.X.; Deng, Y.T.; Sun, Y.; Lv, D.H.; Wu, C.M.; Huang, L.Z.; et al. Antimicrobial resistance in *Escherichia coli* isolates from food animals, animal food products and companion animals in China. *Vet. Microbiol.* 2010, 146, 85–89. [CrossRef]

32. Wasył, D.; Hoszowski, A.; Zajac, M.; Szulowski, K. Antimicrobial resistance in commensal *Escherichia coli* isolated from animals at slaughter. *Front. Microbiol.* 2013, 4, 221. [CrossRef]

33. Zhang, P.; Shen, Z.; Zhang, C.; Song, L.; Wang, B.; Shang, J.; Yue, X.; Qu, Z.; Li, X.; Wu, L.; et al. Surveillance of antimicrobial resistance among *Escherichia coli* from chicken and swine, China, 2008–2015. *Vet. Microbiol.* 2017, 203, 49–55. [CrossRef]

34. Hassen, B.; Abbassi, M.S.; Ruiz-Ripa, L.; Mama, O.M.; Hassen, A.; Torres, C.; Hammami, S. High prevalence of *mcr-1* encoding colistin resistance and first identification of *blaCTX-M-55* in ESBL/CMY-2-producing *Escherichia coli* isolated from chicken faeces and retail meat in Tunisia. *Int. J. Food Microbiol.* 2020, 318, 108478. [CrossRef] [PubMed]

35. Ibrahim, R.A.; Cryer, T.L.; Lafi, S.Q.; Basha, E.A.; Good, L.; Tarazi, Y.H. Identification of *Escherichia coli* from broiler chickens in Jordan, their antimicrobial resistance, gene characterization and the associated risk factors. *BMC Vet. Res.* 2019, 15, 159. [CrossRef] [PubMed]

36. Sarker, M.S.; Mannan, M.S.; Ali, M.Y.; Bayzid, M.; Ahad, A.; Bupasha, Z.B. Antibiotic resistance of *Escherichia coli* isolated from broilers sold at live bird markets in Chattogram, Bangladesh. *J. Adv. Vet. Anim. Res.* 2019, 6, 272–277. [CrossRef] [PubMed]

37. Animal and Plant Quarantine Agency. *Korean Veterinary Antimicrobial Resistance Monitoring System; APQA Annual Report: Gimcheon, Korea, 2019*, 2019.

38. Usui, M.; Ozawa, S.; Onozato, H.; Kuge, R.; Obata, Y.; Uemae, T.; Ngoc, P.T.; Heriyanto, A.; Chalemchaikit, T.; Makita, K.; et al. Antimicrobial susceptibility of indicator bacteria isolated from chickens in Southeast Asian countries (Vietnam, Indonesia and Thailand). *J. Vet. Med. Sci.* 2014, 76, 685–692. [CrossRef] [PubMed]

39. Lim, J.S.; Choi, D.S.; Kim, Y.J.; Chon, J.W.; Kim, H.S.; Park, H.J.; Moon, J.S.; Wee, S.H.; Seo, K.H. Characterization of *Escherichia coli*-producing extended-spectrum β-Lactamase (ESBL) isolated from chicken slaughterhouses in South Korea. *Foodborne Pathog. Dis.* 2015, 12, 741–748. [CrossRef]

40. Nguyen, N.T.; Nguyen, H.M.; Nguyen, C.V.; Nguyen, T.V.; Nguyen, M.T.; Thai, H.Q.; Ho, M.H.; Thwaites, G.; Ngo, H.T.; Baker, S.; et al. Use of colistin and other critical antimicrobials on pig and chicken farms in southern Vietnam and its association with resistance in commensal *Escherichia coli* bacteria. *Appl. Environ. Microbiol.* 2016, 82, 3727–3735. [CrossRef]

41. Subedi, M.; Luitel, H.; Devkota, B.; Bhattarai, R.K.; Phuyal, S.; Panthi, P.; Shrestha, A.; Chaudhary, D.K. Antibiotic resistance pattern and virulence genes content in avian pathogenic *Escherichia coli* (APEC) from broiler chickens in Chitwan, Nepal. *BMC Vet. Res.* 2018, 14, 113. [CrossRef]

42. Moniri, R.; Dastehgoli, K. Fluoroquinolone-resistant *Escherichia coli* isolated from healthy broilers with previous exposure to fluoroquinolones: Is there a link? *Microb. Ecol. Health Dis.* 2005, 17, 69–74.

43. Eltai, N.O.; Abdifarag, E.A.; Al-Romaini, H.; Wehedy, E.; Mahmoud, M.H.; Alanoud, O.K.; Al-Hajri, M.M.; Thani, A.A.A.L.; Yassine, H.M. Antibiotic resistance profile of commensal *Escherichia coli* isolated from broiler chickens in Qatar. *J. Food Prot.* 2018, 81, 302–307. [CrossRef]

44. Seo, K.W.; Shim, J.B.; Lee, Y.J. Emergence of CMY-2-producing *Escherichia coli* in Korean layer parent stock. *Microb. Drug Resist.* 2019, 25, 462–468. [CrossRef]
45. Na, S.H.; Moon, D.C.; Choi, M.J.; Oh, S.J.; Jung, D.Y.; Sung, E.J.; Kang, H.Y.; Hyun, B.H.; Lim, S.K. Antimicrobial resistance and molecular characterization of extended-spectrum β-lactamase-producing Escherichia coli isolated from ducks in South Korea. Foodborne Pathog. Dis. 2019, 16, 799–806. [CrossRef] [PubMed]

46. FDA. Guidance for Industry: Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling; Silver Spring: Montgomery County, MD, USA, 2013.

47. Lee, H.J.; Cho, S.H.; Shin, D.; Kang, H.S. Prevalence of antibiotic residues and antibiotic resistance in isolates of chicken meat in Korea. Korean J. Food Sci. Anim. Resour. 2018, 38, 1055–1063. [CrossRef] [PubMed]

48. Seo, K.W.; Shim, J.B.; Kim, Y.B.; Son, S.H.; Bi Noh, E.; Yoon, S.; Lim, S.K.; Ju Lee, Y. Impacts and characteristics of antimicrobial resistance of Escherichia coli isolates by administration of third-generation cephalosporins in layer hatcheries. Vet. Microbiol. 2020, 243, 108643. [CrossRef] [PubMed]

49. Hiki, M.; Kawanishi, M.; Abo, H.; Kojima, A.; Koike, R.; Hamamoto, S.; Asai, T. Decreased resistance to broad-spectrum cephalosporin in Escherichia coli from healthy broilers at farms in Japan after voluntary withdrawal of ceftiofur. Foodborne Pathog. Dis. 2015, 12, 639–643. [CrossRef]

50. Dutil, L.; Irwin, R.; Finley, R.; Ng, L.K.; Avery, B.; Boerlin, P.; Bourgault, A.M.; Cole, L.; Daignault, D.; Desruisseaux, A.; et al. Ceftiofur resistance in Salmonella enterica serovar Heidelberg from chicken meat and humans, Canada. Emerg. Infect. Dis. 2010, 16, 48–54. [CrossRef]

51. Bevan, E.R.; Jones, A.M.; Hawkey, P.M. Global epidemiology of CTX-M β-lactamases: Temporal and geographical shifts in genotype. J. Antimicrob. Chemother. 2017, 72, 2145–2155. [CrossRef]

52. Rao, L.; Lv, L.; Zeng, Z.; Chen, S.; He, D.; Chen, X.; Wu, C.; Wang, Y.; Yang, T.; Wu, P.; et al. Increasing prevalence of extended-spectrum cephalosporin-resistant Escherichia coli in food animals and the diversity of CTX-M genotypes during 2003–2012. Vet. Microbiol. 2014, 172, 534–541. [CrossRef]

53. Choi, M.J.; Lim, S.K.; Jung, S.C.; Ko, K.S. Comparisons of CTX-M-producing Escherichia coli isolates from humans and animals in South Korea. J. Bacteriol. Virol. 2014, 44, 44–51. [CrossRef]

54. Kang, C.I.; Cha, M.K.; Kim, S.H.; Ko, K.S.; Wi, Y.M.; Chung, D.R.; Peck, K.R.; Lee, N.Y.; Song, J.H. Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli over a 6-year period. J. Korean Med. Sci. 2013, 28, 998–1004. [CrossRef]

55. Lee, S.G.; Jeong, S.H.; Lee, H.; Kim, C.K.; Lee, Y.; Koh, E.; Chong, Y.; Lee, K. Spread of CTX-M-type extended-spectrum β-lactamases among bloodstream isolates of Escherichia coli and Klebsiella pneumoniae from a Korean hospital. Diagn. Microbiol. Infect. Dis. 2009, 63, 76–80. [CrossRef]

56. He, D.; Chiuou, J.; Zeng, Z.; Liu, L.; Chen, X.; Zeng, L.; Chan, E.W.C.; Liu, J.H.; Chen, S. Residues distal to the active site contribute to enhanced catalytic activity of variant and hybrid β-lactamases derived from CTX-M-14 and CTX-M-15. Antimicrob. Agents Chemother. 2015, 59, 5976–5983. [CrossRef] [PubMed]

57. Ho, P.L.; Chow, K.H.; Lai, E.L.; Lo, W.U.; Yeung, M.K.; Chan, J.; Chan, P.Y.; Yuen, K.Y. Extensive dissemination of CTX-M-producing Escherichia coli with multidrug resistance to “critically important” antibiotics among food animals in Hong Kong, 2008–2010. J. Antimicrob. Chemother. 2011, 66, 765–768. [CrossRef] [PubMed]

58. Li, J.; Ma, Y.; Hu, C.; Jin, S.; Zhang, Q.; Ding, H.; Ran, L.; Cui, S. Dissemination of cefotaxime-M-producing Escherichia coli isolates in poultry farms, but not swine farms, in China. Foodborne Pathog. Dis. 2010, 7, 1387–1392. [CrossRef] [PubMed]

59. Liu, W.; Chen, L.; Li, H.; Duan, H.; Zhang, Y.; Liang, X.; Li, X.; Zou, M.; Xu, L.; Hawkey, P.M. Novel CTX-M-14 β-lactamase genotype distribution and spread into multiple species of Enterobacteriaceae in Changsha, Southern China. J. Antimicrob. Chemother. 2009, 63, 895–900. [CrossRef] [PubMed]

60. Zheng, H.; Zeng, Z.; Chen, S.; Liu, Y.; Yao, Q.; Deng, Y.; Chen, X.; Lv, L.; Zhuo, C.; Chen, Z.; et al. Prevalence and characterization of CTX-M β-lactamases amongst Escherichia coli isolates from healthy food animals in China. Int. J. Antimicrob. Agents 2012, 39, 305–310. [CrossRef] [PubMed]

61. Ewers, C.; Bethe, A.; Seemler, T.; Guenther, S.; Wieler, L.H. Extended-spectrum β-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: A global perspective. Clin. Microbiol. Infect. 2012, 18, 646–655. [CrossRef]

62. Kojima, A.; Ishii, Y.; Ishihara, K.; Esaki, H.; Asai, T.; Oda, C.; Tamura, Y.; Takahashi, T.; Yamaguchi, K. Extended-spectrum-β-lactamase-producing Escherichia coli strains isolated from farm animals from 1999 to 2002: Report from the Japanese veterinary antimicrobial resistance monitoring program. Antimicrob. Agents Chemother. 2005, 49, 3533–3537. [CrossRef]
63. Girlich, D.; Poirol, L.; Carattoli, A.; Kempf, I.; Lartigue, M.F.; Bertini, A.; Nordmann, P. Extended-spectrum \( \beta \)-lactamase CTX-M-1 in *Escherichia coli* isolates from healthy poultry in France. *Appl. Environ. Microbiol.* 2007, 73, 4681–4685. [CrossRef]

64. Kola, A.; Kohler, C.; Peifer, Y.; Schwab, F.; Kühn, K.; Schulz, K.; Balau, V.; Breitbach, K.; Bast, A.; Witte, W.; et al. High prevalence of extended-spectrum-\( \beta \)-lactamase-producing *Enterobacteriaceae* in organic and conventional retail chicken meat, Germany. *J. Antimicrob. Chemother.* 2012, 67, 2631–2634. [CrossRef]

65. Philippon, A.; Arlet, G.; Jacoby, G.A. Plasmid-determined AmpC-type \( \beta \)-lactamases. *Antimicrob. Agents Chemother.* 2002, 46, 1–11. [CrossRef]

66. Yoo, J.S.; Byeon, J.; Yang, J.; Yoo, J.I.; Chung, G.T.; Lee, Y.S. High prevalence of extended-spectrum \( \beta \)-lactamases and plasmid-mediated AmpC \( \beta \)-lactamases in *Enterobacteriaceae* isolated from long-term care facilities in Korea. *Diagn. Microbiol. Infect. Dis.* 2010, 67, 261–265. [CrossRef][PubMed]

67. Storberg, V. ESBL-producing *Enterobacteriaceae* in Africa—a non-systematic literature review of research published 2008–2012. *Infect. Ecol. Epidemiol.* 2014, 4, 50–55.

68. Hornish, R.; Katarzki, S. Cephalosporins in veterinary medicine—Ceftiofur use in food animals. *Curr. Top. Med. Chem.* 2005, 2, 717–731. [CrossRef][PubMed]

69. Mulvey, M.R.; Bryce, E.; Boyd, D.A.; Ofner-Agostini, M.; Land, A.M.; Simor, A.E.; Paton, S. Molecular characterization of cefoxitin-resistant *Escherichia coli* from Canadian hospitals. *Antimicrob. Agents Chemother.* 2005, 49, 358–365. [CrossRef][PubMed]

70. Hasman, H.; Mevius, D.; Veldman, K.; Olesen, I.; Aarestrup, F.M. \( \beta \)-Lactamases among extended-spectrum \( \beta \)-lactamase (ESBL)-resistant *Salmonella* from poultry, poultry products and human patients in The Netherlands. *J. Antimicrob. Chemother.* 2005, 56, 115–121. [CrossRef][PubMed]

71. Woodford, N.; Reddy, S.; Fagan, E.J.; Hill, R.L.R.; Hopkins, K.L.; Kaufmann, M.E.; Kistler, J.; Palepou, M.F.I.; Pike, R.; Ward, M.E.; et al. Wide geographic spread of diverse acquired AmpC \( \beta \)-lactamases among *Escherichia coli* and *Klebsiella spp.* in the UK and Ireland. *J. Antimicrob. Chemother.* 2007, 59, 102–105. [CrossRef]

72. Batchelor, M.; Thrallfall, E.J.; Liebana, E. Cephalosporin resistance among animal-associated *Enterobacteria*: A current perspective. *Expert Rev. Anti. Infect. Ther.* 2005, 3, 403–417. [CrossRef]

73. Liu, B.T.; Yang, Q.E.; Li, L.; Sun, J.; Liao, X.P.; Fang, L.X.; Yang, S.S.; Deng, H.; Liu, Y.H. Dissemination and characterization of plasmids carrying *qxAB*-bla\(_{\text{CTX-M}}\) genes in *Escherichia coli* isolates from food-producing animals. *PLoS ONE* 2013, 8, e73947. [CrossRef]

74. Lv, L.; Partridge, S.R.; He, L.; Zeng, Z.; He, D.; Ye, J.; Liu, J.H. Genetic characterization of IncI2 plasmids carrying *bla\(_{\text{CTX-M-55}}\)* spreading in both pets and food animals in China. *Antimicrob. Agents Chemother.* 2013, 57, 2824–2827. [CrossRef]

75. Wong, M.H.Y.; Liu, L.; Yan, M.; Chan, E.W.C.; Chen, S. Dissemination of IncI2 plasmids that harbor the *bla\(_{\text{CTX-M}}\)* element among clinical *Salmonella* isolates. *Antimicrob. Agents Chemother.* 2015, 59, 5026–5028. [CrossRef]

76. Pai, H.; Seo, M.R.; Choi, T.Y. Association of *QnrB* determinants and production of extended-spectrum \( \beta \)-lactamases or plasmid-mediated AmpC \( \beta \)-lactamases in clinical isolates of *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* 2007, 51, 366–368. [CrossRef][PubMed]

77. Robicsek, A.; Jacoby, G.A.; Hooper, D.C. The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect. Dis.* 2006, 6, 629–644. [CrossRef]

78. Strahtilevitz, J.; Jacoby, G.A.; Hooper, D.C.; Robicsek, A. Plasmid-mediated quinolone resistance: A multifaceted threat. *Clin. Microbiol. Rev.* 2009, 22, 644–649. [CrossRef][PubMed]

79. Grami, R.; Mansour, W.; Mehrizi, W.; Bouallégue, O.; Boujaâfar, N.; Madec, J.; Haenni, M. Impact of food animal trade on the spread of *mcr-1*-mediated colistin resistance, Tunisia. *Eurosurveillance* 2016, 21, 1–5. [CrossRef][PubMed]

80. Han, S.; Kim, J.S.; Hong, C.K.; Park, S.H.; Kim, H.S.; Yu, J.K.; Park, J.; Kim, J.; Lee, S.M.; Oh, Y.H. Identification of an extensively drug-resistant *Escherichia coli* clinical strain harboring *mcr-1* and *bla\(_{\text{NDM-1}}\)* in Korea. *J. Antibiot.* 2020. [CrossRef]

81. Nukui, Y.; Ayibieke, A.; Taniguchi, M.; Aiso, Y.; Shibuya, Y.; Sonobe, K.; Nakajima, J.; Kanehira, S.; Hadano, Y.; Tohda, S.; et al. Whole-genome analysis of EC129, an NDM-5-, CTX-M-14-, OXA-10- and MCR-1-co-producing *Escherichia coli* ST167 strain isolated from Japan. *J. Glob. Antimicrob. Resist.* 2019, 18, 148–150. [CrossRef]
82. Oh, S.S.; Song, J.; Kim, J.; Shin, J. Increasing prevalence of multidrug-resistant mcr-1-positive Escherichia coli isolates from fresh vegetables and healthy food animals in South Korea. *Int. J. Infect. Dis.* 2020, 92, 53–55. [CrossRef]

83. Wu, C.; Wang, Y.; Shi, X.; Wang, S.; Ren, H.; Shen, Z.; Wang, Y.; Lin, J.; Wang, S. Rapid rise of the ESBL and mcr-1 genes in *Escherichia coli* of chicken origin in China, 2008–2014. *Emerg. Microbes Infect.* 2018, 7, 30. [CrossRef]

84. Monte, D.F.; Mem, A.; Fernandes, M.R.; Cerdeira, L.; Esposito, F.; Galvão, J.A.; Franco, B.D.G.M.; Lincopan, N.; Landgraf, M. Chicken meat as a reservoir of colistin-resistant *Escherichia coli* strains carrying mcr-1 genes in South America. *Antimicrob. Agents Chemother.* 2017, 61, e02718-16. [CrossRef]

85. Maciuca, I.E.; Cummins, M.L.; Cozma, A.P.; Rimbu, C.M.; Guguianu, E.; Panzaru, C.; Licker, M.; Szekely, E.; Flonta, M.; Djordjevic, S.P.; et al. Genetic Features of mcr-1 mediated colistin resistance in CMY-2-producing *Escherichia coli* from Romanian Poultry. *Front. Microbiol.* 2019, 10, 02267. [CrossRef]

86. Maamar, E.; Alonso, C.A.; Hamzaoui, Z.; Dakhli, N.; Abbassi, M.S.; Ferjani, S.; Saidani, M.; Boutiba-Ben Boubaker, I.; Torres, C. Emergence of plasmid-mediated colistin-resistance in CMY-2-producing *Escherichia coli* of lineage ST2197 in a Tunisian poultry farm. *Int. J. Food Microbiol.* 2018, 269, 60–63. [CrossRef] [PubMed]

87. Millán, B.; Ghiglione, B.; Díaz, T.; Gutkind, G.; Araque, M. CTX-M-14 β-lactamase-producing *Citrobacter freundii* isolated in Venezuela. *Ann. Clin. Microbiol. Antimicrob.* 2011, 10, 22. [CrossRef] [PubMed]

88. Song, W.; Kim, J.; Bae, I.K.; Jeong, S.H.; Seo, Y.H.; Shin, J.H.; Jang, S.J.; Uh, Y.; Shin, J.H.; Lee, M.K.; et al. Chromosome-encoded AmpC and CTX-M extended-spectrum β-lactamases in clinical isolates of *Proteus mirabilis* from Korea. *Antimicrob. Agents Chemother.* 2011, 55, 1414–1419. [CrossRef] [PubMed]

89. Crémet, L.; Carroff, N.; Dauvergne, S.; Reynaud, A.; Lepelletier, D.; Corvec, S. Prevalence of plasmid-mediated quinolone resistance determinants in ESBL *Enterobacteriaceae* clinical isolates over a 1-year period in a French hospital. *Pathol. Biol.* 2011, 59, 151–156. [CrossRef] [PubMed]

90. Poirel, L.; Decousser, J.W.; Nordmann, P. Insertion sequence ISEcp1B is involved in expression and mobilization of the blaCTXM β-lactamase gene. *Antimicrob. Agents Chemother.* 2003, 47, 2938–2945. [CrossRef]

91. Cao, V.; Lambert, T.; Courvalin, P. ColEl1-like plasmid pIP843 of *Klebsiella pneumoniae* encoding extended-spectrum β-lactamase CTX-M-17. *Antimicrob. Agents Chemother.* 2002, 46, 1212–1217. [CrossRef]

92. Karim, A.; Poirel, L.; Nagarajan, S.; Nordmann, P. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISecp1. *FEMS Microbiol. Lett.* 2001, 201, 237–241.

93. Sun, Y.; Zeng, Z.; Chen, S.; Ma, J.; He, L.; Liu, Y.; Deng, Y.; Lei, T.; Zhao, J.; Liu, J.H. High prevalence of blaCTXM extended-spectrum β-lactamase genes in *Escherichia coli* isolates from pets and emergence of CTX-M-64 in China. *Clin. Microbiol. Infect.* 2010, 16, 1475–1481. [CrossRef]